BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia Available online 14 August 2014 http://www.sciencedirect.com/science/article/pii/S1535610814002980 source: Cancer Cell